XNCR

Xencor, Inc.

Xencor Inc is engaged in the field of biotechnology. The United States-based firm develops drugs to combat severe diseases such as allergies and cancers.

Xencor, Inc. (XNCR) is scored daily on Deltasharpe Prism against Healthcare sector peers across five pillars: Value, Growth, Profitability, Momentum and Revisions.

Quantitative Factor Evaluation • Updated

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-15 B- (2.9) C- (2.0) C+ (2.6) A+ (4.6) C+ (2.6) B- (3.0)
2026-11-08 B- (2.9) C (2.5) C+ (2.6) A+ (4.7) C+ (2.6) B- (3.1)
2026-11-01 B- (2.9) D+ (1.7) B- (3.1) A+ (4.6) C+ (2.7) B- (3.0)
2026-10-25 B- (2.9) D+ (1.7) B- (3.1) A- (4.1) C+ (2.6) B- (2.9)

Showing the last month only. Subscribe for the full factor score history.

For more — Subscribe